GNT Pharma's positive Phase 3 clinical trial results on 'Nelonemdaz' for stroke
South Korean GNT Pharma Co. Ltd announced on the 13th of this month, that administering their stroke treatment drug 'Nelonemdaz' to patients within one hour of arrival at the emergency room showed nearly a five-fold improvement in disability compared to a placebo treatment. T he chief investigator of the Phase 3 trial at Seoul Asan Hospital's Neurology Department, presented the key findings at ISC 2024 held at the Phoenix Convention Center in Arizona, USA. It has been reported that the Phase 3 trial of Nelonemdaz targeted severe stroke patients receiving intravenous thrombolysis within 12 hours of onset. The 496 patients in this trial received medication within 7 hours of onset upon arrival at the emergency room and underwent thrombolysis simultaneously, analyzing disability improvement and safety 12 weeks later. The efficacy of Nelonemdaz was found to be related to the time of medication administration and thrombolysis. Particularly, among 47 patients who promptly rec...